Cidara Therapeutics Past Earnings Performance
Past criteria checks 0/6
Cidara Therapeutics has been growing earnings at an average annual rate of 18.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 42.7% per year.
Key information
17.5%
Earnings growth rate
38.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 47.5% |
| Return on equity | -381.9% |
| Net Margin | -54.3% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth
Sep 28
Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop
Apr 17Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year
Mar 25We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely
Mar 14Cidara spikes on $11M milestone payment from partner Mundipharma
Oct 04Cidara begins dosing of antiviral CD388 in trial for preventing influenza
Sep 13Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M
Aug 09Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts
Dec 17Rainbows and Unicorns: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Just Became A Lot More Optimistic
Aug 17Is Cidara Therapeutics (NASDAQ:CDTX) Weighed On By Its Debt Load?
Aug 04Cidara Therapeutics: Rezafungin Data Could Bring Value
Jul 20We Think Some Shareholders May Hesitate To Increase Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) CEO Compensation
Jun 17Analysts' Revenue Estimates For Cidara Therapeutics, Inc. (NASDAQ:CDTX) Are Surging Higher
Mar 02Earnings Beat: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Feb 28Did Cidara Therapeutics, Inc. (NASDAQ:CDTX) Insiders Buy Up More Shares?
Feb 20Revenue & Expenses BreakdownBeta
How Cidara Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 64 | -23 | 18 | 69 |
| 30 Sep 23 | 57 | -31 | 15 | 0 |
| 30 Jun 23 | 85 | -8 | 17 | 0 |
| 31 Mar 23 | 83 | -9 | 18 | 0 |
| 31 Dec 22 | 64 | -30 | 18 | 0 |
| 30 Sep 22 | 61 | -33 | 20 | 0 |
| 30 Jun 22 | 28 | -63 | 19 | 0 |
| 31 Mar 22 | 54 | -44 | 19 | 0 |
| 31 Dec 21 | 50 | -42 | 19 | 0 |
| 30 Sep 21 | 46 | -47 | 18 | 0 |
| 30 Jun 21 | 41 | -47 | 17 | 0 |
| 31 Mar 21 | 12 | -74 | 17 | 0 |
| 31 Dec 20 | 12 | -75 | 16 | 0 |
| 30 Sep 20 | 10 | -67 | 16 | 0 |
| 30 Jun 20 | 27 | -47 | 17 | 0 |
| 31 Mar 20 | 23 | -42 | 17 | 0 |
| 31 Dec 19 | 21 | -41 | 16 | 0 |
| 30 Sep 19 | 19 | -39 | 15 | 0 |
| 30 Jun 19 | 0 | -56 | 14 | -25 |
| 31 Mar 19 | 0 | -69 | 14 | -13 |
| 31 Dec 18 | 0 | -69 | 14 | 0 |
| 30 Sep 18 | 0 | -70 | 14 | 10 |
| 30 Jun 18 | 0 | -69 | 13 | 44 |
| 31 Mar 18 | 0 | -59 | 13 | 46 |
| 31 Dec 17 | 0 | -56 | 13 | 0 |
| 30 Sep 17 | 0 | -57 | 13 | 44 |
| 30 Jun 17 | 0 | -57 | 13 | 43 |
| 31 Mar 17 | 0 | -52 | 13 | 39 |
| 31 Dec 16 | 0 | -48 | 13 | 36 |
| 30 Sep 16 | 0 | -44 | 12 | 32 |
| 30 Jun 16 | 0 | -41 | 11 | 30 |
| 31 Mar 16 | 0 | -35 | 10 | 26 |
| 31 Dec 15 | 0 | -32 | 9 | 23 |
| 30 Sep 15 | 0 | -27 | 8 | 19 |
| 30 Jun 15 | 0 | -21 | 7 | 15 |
| 31 Mar 15 | 0 | -18 | 5 | 11 |
| 31 Dec 14 | 0 | -12 | 3 | 7 |
| 30 Sep 14 | 0 | -8 | 2 | 3 |
Quality Earnings: CDTX is currently unprofitable.
Growing Profit Margin: CDTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CDTX is unprofitable, but has reduced losses over the past 5 years at a rate of 18.4% per year.
Accelerating Growth: Unable to compare CDTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CDTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: CDTX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.